title: Acetylsalicylic acid resistance risk factors in patients with myocardial infarction.
abstract: BACKGROUND
  Despite its commonly recognized benefits in the cardiovascular disease setting, an issue of resistance to this drug has lately emerged. The aim of this research was assessment of the phenomenon of acetylsalicylic acid (ASA) resistance and its risk factors in patients treated for myocardial infarction.
  
  
  METHODS
  This study is a post-hoc analysis of a previous prospective study with approximately 200 patients treated for myocardial infarction with a coated formulation of ASA. The population was divided into two subgroups according to the response to ASA. ASA responsiveness was assessed using the arachidonic acid-dependent platelet aggregation (ASPI-test). The measurements were performed using the technique of impedance aggregometry.
  
  
  RESULTS
  The prevalence of aspirin resistance among the study population was 6.2%. All analyzed aggregometric parameters (including ASPI-test, adenosine diphosphate dependent platelet aggregation - ADP-test, bleeding time measurement) showed significant differences between both subgroups. ASA resistant patients had higher concentrations of brain natriuretic peptide (BNP), high-sensitivity C-reactive protein (hs-CRP), leukocytes (WBC) and platelets (PLT) but lower concentrations of hemoglobin (HGB). The temporal point analysis for both subgroups showed aspirin resistance incidence peak in patients at 9 months after myocardial infarction.
  
  
  CONCLUSIONS
  The prevalence of aspirin resistance in our study population is comparable with rates reported in literature among patients with cardiovascular diseases. There is a possible relation between aspirin resistance and clopidogrel resistance. Presence did not affect the incidence of the clinical end-points.
authors.affiliation: Department of Pharmacology and Therapeutics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. Electronic address: wioletaplazuk@o2.pl.
authors.forename: Wioleta
authors.initials: W
authors.lastname: Stolarek
authors.affiliation: Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
authors.forename: Michał
authors.initials: M
authors.lastname: Kasprzak
authors.affiliation: Department of Pharmacology and Therapeutics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland; Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
authors.forename: Karolina
authors.initials: K
authors.lastname: Obońska
authors.affiliation: Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland; Department of Principles of Clinical Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Ostrowska
authors.affiliation: Department of Pharmacology and Therapeutics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
authors.forename: Michał
authors.initials: M
authors.lastname: Wiciński
authors.affiliation: Department of Health Promotion, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
authors.forename: Aldona
authors.initials: A
authors.lastname: Kubica
authors.affiliation: Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
authors.forename: Jacek
authors.initials: J
authors.lastname: Kubica
authors.affiliation: Department of Pharmacology and Therapeutics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland; Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Grześk
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D000368:Aged; D016718:Arachidonic Acid / Q000494:pharmacology; D001241:Aspirin / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000378:metabolism; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy*; D020097:Natriuretic Peptide, Brain / Q000378:metabolism; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D015995:Prevalence; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D010975:Platelet Aggregation Inhibitors; D020097:Natriuretic Peptide, Brain; D016718:Arachidonic Acid; D000244:Adenosine Diphosphate; D002097:C-Reactive Protein; D001241:Aspirin
keywords: ASA; Acetylsalicylic acid; Aspirin resistance; Myocardial infarction